This is not a new issue. In fact, the ACSH has published numerous articles on this over the years, beginning in 2017. [1] Currently, there is no transparent review process for the assessments of the IARC Monographs program, even when there is clear counter-evidence from many other respected organizations. This resulted in the IARC assessment of glyphosate as the central document in billions of dollars of litigation that ultimately resulted in an $11 billion settlement in 2020 that resolved the bulk of the lawsuits claiming that Roundup (glyphosate) caused cancer.
I hope that we are finally at a place when a few influential scientists with integrity will have the courage to speak out and demand that the 2015 IARC assessment of glyphosate be retracted or revised.
Background
Roundup (glyphosate) is the world’s best-selling weedkiller and has been used for over 45 years. It is effective against a wide variety of weeds and has lower toxicity compared to other products it has replaced (such as atrazine and alachlor).
In 2015, IARC classified glyphosate as “probably carcinogenic to humans.” IARC, based in Lyon, France, is a semi-autonomous unit of the WHO, the health agency for the United Nations. Since 1971, IARC has evaluated over 1000 chemicals or substances for inclusion in “IARC Monographs on the Identification of the of the Carcinogenic Risk to Humans” series. Two-thirds of the funding of the IARC Monograph program comes from U.S. agencies, with grants from the National Cancer Institute (NCI) and the National Institute of Environmental Health Sciences (NIEHS) totaling almost a million dollars per year.
The purpose of the IARC Monographs program is to evaluate the available scientific evidence to determine the likelihood that a chemical causes cancer. The evaluation is carried out by a “working group of independent international experts.” But how independent are they really? Most U.S. scientists are dependent on grants and contracts from U.S. agencies such as the NCI and NIEHS that support IARC. It would be foolhardy to speak out against IARC, which could threaten their standing in the scientific community and, therefore, their livelihood.
What Do Other Agencies Say?
IARC is the only agency that has concluded that glyphosate poses a carcinogenic risk. The following is a list of agencies that have concluded that glyphosate is not carcinogenic:
- US Environmental Protection Agency
- Health Canada
- European Food Safety Authority
- European Chemicals Agency
- Food and Agriculture Organization of the United Nations
- French Agency for Food, Environmental and Occupational Health & Safety
- German Federal Institute for Risk Assessment
- Australian Pesticides and Veterinary Medicine Authority
- Federal Food Safety and Veterinary Office (Switzerland)
- Environmental Protection Authority (New Zealand)
- National Health Surveillance Agency (Brazil)
- Food Safety Commissions of Japan
- Rural Development Association (S. Korea)
“Our scientists left no stone unturned in conducting this review. They had access to all relevant data and information from federal and provincial governments, international regulatory agencies, published scientific reports, and multiple pesticide manufacturers. To help ensure an unbiased assessment of the information, Health Canada selected a group of 20 of its own scientists who were not involved in the 2017 re-evaluation to evaluate the notices of objection”. Health Canada
All of the other agencies conducted similarly detailed reviews. So why was IARC the only Agency to consider glyphosate a “probable human carcinogen”?
What is the basis for the IARC Classification?
- Evidence in humans: IARC excluded the results from the largest and most comprehensive study on human exposure to glyphosate, the Agricultural Health Study, led by scientists at the NCI. This study examined 54,000 pesticide applicators in Iowa and North Carolina. The reason given for not including this study was that when the IARC working group met in 2015, the results were not yet published. When the results were finally published in 2018, the paper reported no significant increases in 20 different tumor types, including Non-Hodgkin’s Lymphoma. However:
- At least one group member had seen the unpublished results and knew that they found no evidence of a link between glyphosate and cancer but chose not to reveal this information at the meeting.
- There are questions about why the data on Non-Hodgkin’s lymphoma was not published before the IARC meeting, even though draft papers were prepared containing the data.
- Cherry-picked results from animal studies: IARC primarily based its assessment of glyphosates potential carcinogenicity on several rodent studies. Within the same study, IARC’s experts ignored the results showing no increase in tumor incidence and selected a few positive results.
- Changes in drafts: Draft versions of the IARC glyphosate assessment showed that negative conclusions about glyphosate leading to tumors in animal studies were replaced or deleted and neutral or positive statements were added in their place.
- Hazard vs. Risk: Unlike the vast majority of scientific agencies, IARC measures hazard: considering whether the chemical could cause cancer under any circumstance instead of risk: determining the likelihood that a chemical will cause cancer. To get a fuller discussion, see my previous article on this issue.
Scientific Community Response
The response from the scientific community has been to try and win the public debate by accusing the critics of IARC of being in the pockets of corporations.
Instead of welcoming and addressing criticism of IARC, in a 2015 letter and commentary published in the journal, Environmental Health Perspectives, 124 scientists argue that the criticisms of IARC by a “vocal minority” may denigrate the process that has served public health well for many years. It is easy to see why so many scientists signed this letter. Their livelihood often depends on grants from NCI and NIEHS, the Agencies that support IARC, and criticism involving self-examination is never welcome in the scientific community.
Take a minute to review the reported conflicts of interest in this letter. To begin with
“This work was conducted with no direct funding, but was supported in part by the Intramural Research Program of the NIH (NCI and NIEHS).” [emphasis added]
Many signators now serve as expert witnesses for plaintiffs in litigation around a host of chemicals and their effects. Others have served or continue to serve on IARC monograph working groups.
One of IARC’s stated core principles is that the expert scientists serving in their working groups should be independent with no conflicts of interest. This has been used to ban scientists who work for industry from being in their working groups.
“No matter how loud the voice, no matter how many people are speaking it, doesn’t make it true. But how can I tell?
One tell-tale sign is if your voice is suppressed or vilified when you try to question that voice.”
Charles Glassman MD
Conflicts of interest are not simply financial but can often be belief-driven. The deliberate exclusion of scientists with conflicting interests in favor of glyphosate because of “bias” in IARC’s glyphosate study is an example. But when you cherry-pick your experts, you facilitate group-think, another bias that stifles the discourse that lies at the heart of science and these deliberations.
It is much easier to sign a letter of support than to actually examine the criticisms that may result in changes to a process that has benefited a select few scientists (those chosen to be on IARC Working Group panels) over the years. Despite all the back and forth about who was financially remunerated and by whom, it is important to recognize that there has been no scientific rationale put forth to justify the actions taken by IARC on glyphosate.
Conclusions
The U.S., as the major funder of the IARC Monographs program, should insist that IARC develop a transparent review and appeals process. In addition, the U.S. needs to ensure that IARC’s conflict of interest policy is changed to include conflicts such as working as litigation consultants in trial lawsuits. Finally, as stated earlier, the IARC assessment of glyphosate should be retracted or revised.
“The systematic exclusion by IARC of researchers with real or perceived industry conflicts of interest decreases the likelihood that the strongest arguments defending a suspect agent against claims of carcinogenicity will be presented and discussed during Working Group deliberations, and thus increases the probability that the agent will be classified as posing a carcinogenic hazard to humans, regardless of the strength or weakness of evidence supporting that conclusion.”
R Tarone Conflicts of interest, bias, and the IARC Monographs Program
[1] Who is Afraid of Roundup?, EPA Refutes Study Claiming Glyphosate Boosts Cancer Risk, Claims That Criticism Of IARC Are Industry-Driven Do IARC More Harm Than Good, Roundup Cover Up? Glyphosate Funny Business At IARC, Round Up Cover-Up, Part 2: Why Did IARC Exclude Selective Evidence?
Sources: Reuters In glyphosate review, WHO cancer agency edited out “non-carcinogenic findings”
Reuters Cancer agency left in the dark over glyphosate evidence
IARC Monographs on the Identification of the of the Carcinogenic Risk to Humans
